The role of opioidergic genes in the treatment outcome of drug addiction pharmacotherapy: A systematic review (Q38270731)

1 September 2017

The role of opioidergic genes in the treatment outcome of drug addiction pharmacotherapy: A systematic review. (English)

1 reference

1 September 2017

0 references

0 references

Isabelle E Bauer

1

1 reference

PubMed ID

25418439

1 September 2017

Jair C Soares

series ordinal

2

1 reference

PubMed ID

25418439

1 September 2017

David A Nielsen

series ordinal

3

1 reference

1 September 2017

21 November 2014

1 reference

American Journal on Addictions

1 September 2017

1 reference

Genetic influences on impulsivity, risk taking, stress responsivity and vulnerability to drug abuse and addiction

1 September 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1521-0391.2014.12172.X

Pharmacogenetics and human molecular genetics of opiate and cocaine addictions and their treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1521-0391.2014.12172.X

The endogenous opioid system: a common substrate in drug addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1521-0391.2014.12172.X

Decreased volume of the brain reward system in alcoholism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1521-0391.2014.12172.X

Pharmacogenetic approaches to the treatment of alcohol addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1521-0391.2014.12172.X

Pharmacogenetics of OPRM1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1521-0391.2014.12172.X

Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1521-0391.2014.12172.X

A polymorphism of the mu-opioid receptor gene (OPRM1) and sensitivity to the effects of alcohol in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1521-0391.2014.12172.X

Mu opioid receptor gene polymorphisms and heroin dependence in Asian populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1521-0391.2014.12172.X

Low frequency genetic variants in the μ-opioid receptor (OPRM1) affect risk for addiction to heroin and cocaine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1521-0391.2014.12172.X

Effects of opioid receptor gene variation on targeted nalmefene treatment in heavy drinkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1521-0391.2014.12172.X

A genetic determinant of the striatal dopamine response to alcohol in men

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1521-0391.2014.12172.X

An Intronic Variant in OPRD1 Predicts Treatment Outcome for Opioid Dependence in African-Americans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1521-0391.2014.12172.X

Increased abundance of opioid receptor heteromers after chronic morphine administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1521-0391.2014.12172.X

Mice deficient for delta- and mu-opioid receptors exhibit opposing alterations of emotional responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1521-0391.2014.12172.X

The OPRD1 and OPRK1 loci in alcohol or drug dependence: OPRD1 variation modulates substance dependence risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1521-0391.2014.12172.X

Association of OPRD1 polymorphisms with heroin dependence in a large case-control series

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1521-0391.2014.12172.X

Case-control association analysis of polymorphisms in the δ-opioid receptor, OPRD1, with cocaine and opioid addicted populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1521-0391.2014.12172.X

The dynorphin/κ-opioid receptor system and its role in psychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1521-0391.2014.12172.X

Association of the kappa-opioid system with alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1521-0391.2014.12172.X

The association of genetic polymorphisms in the κ-opioid receptor 1 gene with body weight, alcohol use, and withdrawal symptoms in patients with methadone maintenance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1521-0391.2014.12172.X

Genetic susceptibility to heroin addiction: a candidate gene association study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1521-0391.2014.12172.X

A variant on the kappa opioid receptor gene (OPRK1) is associated with stress response and related drug craving, limbic brain activation and cocaine relapse risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1521-0391.2014.12172.X

Effects of naltrexone and nalmefene on subjective response to alcohol among non-treatment-seeking alcoholics and social drinkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1521-0391.2014.12172.X

Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1521-0391.2014.12172.X

Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1521-0391.2014.12172.X

Naltrexone effects on alcohol consumption in a clinical laboratory paradigm: temporal effects of drinking

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1521-0391.2014.12172.X

Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1521-0391.2014.12172.X

A micro opioid receptor gene polymorphism (A118G) and naltrexone treatment response in adherent Korean alcohol-dependent patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1521-0391.2014.12172.X

Genetic moderators of naltrexone's effects on alcohol cue reactivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1521-0391.2014.12172.X

A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1521-0391.2014.12172.X

An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1521-0391.2014.12172.X

OPRM1 Asn40Asp predicts response to naltrexone treatment: a haplotype-based approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1521-0391.2014.12172.X

Pharmacogenetics of naltrexone in asian americans: a randomized placebo-controlled laboratory study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1521-0391.2014.12172.X

Naltrexone alone and with sertraline for the treatment of alcohol dependence in Alaska natives and non-natives residing in rural settings: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1521-0391.2014.12172.X

Moderators of naltrexone's effects on drinking, urge, and alcohol effects in non-treatment-seeking heavy drinkers in the natural environment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1521-0391.2014.12172.X

Genetic variation in OPRD1 and the response to treatment for opioid dependence with buprenorphine in European-American females.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1521-0391.2014.12172.X

Association of genetic variation in pharmacodynamic factors with methadone dose required for effective treatment of opioid addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1521-0391.2014.12172.X

Genetic polymorphisms in the opioid receptor mu1 gene are associated with changes in libido and insomnia in methadone maintenance patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1521-0391.2014.12172.X

Impact of genetic polymorphisms in ABCB1, CYP2B6, OPRM1, ANKK1 and DRD2 genes on methadone therapy in Han Chinese patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1521-0391.2014.12172.X

Association of dopamine and opioid receptor genetic polymorphisms with response to methadone maintenance treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1521-0391.2014.12172.X

Vaccine pharmacotherapy for the treatment of cocaine dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1521-0391.2014.12172.X

The κ-opioid receptor gene as a predictor of response in a cocaine vaccine clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1521-0391.2014.12172.X

OPRM1 A118G genotype fails to predict the effectiveness of naltrexone treatment for alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1521-0391.2014.12172.X

10.1111/J.1521-0391.2014.12172.X

21 January 2018

Identifiers

DOI

1 reference

1 September 2017

1 reference

PubMed ID

25418439